NCT01446250 - Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Hepatitis C

Interventions

DRUG

Alisporivir

ALV 200 mg soft gel capsules administered orally

DRUG

Boceprevir

BOC 800 mg (4 x 200 mg soft gel capsules) administered orally

DRUG

Peginterferon alfa-2a

PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

DRUG

Ribavirin

RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Trial Locations (2)

Novartis Investigational Site, Baltimore

Novartis Investigational Site, Beverly Hills